StoneX Group’s Lucid Diagnostics LUCD Stock Holding History

StoneX Group’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,608	Closed	-$16.8K	–	1522
2026 Q1	$16.8K	Buy	+14,608	New	+$18.6K	﹤0.01%	835

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

StoneX Group's LUCD Position: Q2 2026 in Review

StoneX Group sold out of Lucid Diagnostics (LUCD) in Q2 2026, closing a stake of 14,608 shares — an estimated $16.8K sold.

StoneX Group first reported a position in LUCD in Q1 2026 and held it in 1 quarter. The position peaked at $16.8K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

StoneX Group reported no remaining Lucid Diagnostics position as of Q2 2026 after selling out during the quarter.
StoneX Group sold 14,608 Lucid Diagnostics shares in Q2 2026, an estimated $16.8K.
StoneX Group first reported a position in Lucid Diagnostics in Q1 2026 and held it in 1 quarter.
StoneX Group's Lucid Diagnostics position peaked at $16.8K in Q1 2026.
116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.